[A comparison of efficacy and tolerance of furamag and norbactin in the treatment of acute cystitis in females].
Efficacy and tolerance of furamag and norbactin were compared in a prospective controlled trial with participation of 82 females aged 18-60 years with acute uncomplicated cystitis. All the women were divided into two groups. Group 1 (n=42) received norbactin (norfloxacin) in a dose 400 mg twice a day for 7 days. Group 2 (n=40) was given furamag in a dose 50 mg 3 times a day for 10 days. The results were evaluated 2 weeks after the treatment. The comparison of the treatment results showed that a new nitrofuranic drug furamag has significantly higher clinical and bacteriological efficacy: acute cystitis was cured in 95% patients, eradication of the infective agent occurred in 96.4% patients, tolerance was good in 97.5% patients. Sensitivity of the agents causing acute cystitis to nitrofurans reached 98.2% while to norbactin--only 86%.
Davidov
M I
MI
Mitiagin
P N
PN
Maksiutova
A S
AS
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003556:Cystitis / Q000188:drug therapy* / Q000382:microbiology; D024881:Drug Resistance, Bacterial / Q000187:drug effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D009581:Nitrofurans / Q000008:administration & dosage* / Q000009:adverse effects; D009643:Norfloxacin / Q000008:administration & dosage* / Q000009:adverse effects
D000900:Anti-Bacterial Agents; D009581:Nitrofurans; D009643:Norfloxacin